alfuzosin has been researched along with Recrudescence in 4 studies
alfuzosin: structure given in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 9.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 5.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To determine the effectiveness of alfuzosin on symptom reduction, patients' perceived health-related quality of life (HRQL) improvement, adverse outcomes, treatment failure, and progression to acute urinary retention and prostate surgery in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH) in a 1-year prospective, open-labeled study." | 3.70 | One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. ( Comet, D; Grange, JC; Lukacs, B, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Titos-Arcos, JC | 1 |
| Hallal, H | 1 |
| Andrade, RJ | 1 |
| López Martín, A | 1 |
| Marschall-Kehrel, AD | 1 |
| Mürtz, G | 1 |
| Kramer, G | 1 |
| Jünemann, KP | 1 |
| Madersbacher, H | 1 |
| Hjalmas, K | 1 |
| McNeill, SA | 1 |
| Hargreave, TB | 1 |
| Roehrborn, CG | 1 |
| Lukacs, B | 1 |
| Grange, JC | 1 |
| Comet, D | 1 |
1 trial available for alfuzosin and Recrudescence
| Article | Year |
|---|---|
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Fr | 2005 |
3 other studies available for alfuzosin and Recrudescence
| Article | Year |
|---|---|
[Recurrent hepatocellular lesion due to alfuzosin].
Topics: Adrenergic alpha-1 Receptor Antagonists; Chemical and Drug Induced Liver Injury; Humans; Male; Middl | 2011 |
[A suggested treatment algorithm in nocturnal enuresis with emphasis on partial responders].
Topics: Adolescent; Algorithms; Behavior Therapy; Benzilates; Biofeedback, Psychology; Child; Child, Prescho | 2004 |
One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Family Practice; Follow-Up Studies; Humans; M | 2000 |